These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 2117485)

  • 41. Effect of viral nucleic acid testing on contamination frequency of manufacturing plasma pools.
    Nübling CM; Unkelbach U; Chudy M; Seitz R
    Transfusion; 2008 May; 48(5):822-6. PubMed ID: 18208414
    [TBL] [Abstract][Full Text] [Related]  

  • 42. At what stage should virus inactivation be carried out?
    Dorner F; Barrett PN; Eibl J
    Dev Biol Stand; 1993; 81():137-43. PubMed ID: 8174796
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of manufacturing process parameters on virus inactivation by dry heat treatment at 80 degrees C in factor VIII.
    Roberts PL; Dunkerley C; McAuley A; Winkelman L
    Vox Sang; 2007 Jan; 92(1):56-63. PubMed ID: 17181591
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Characterisation and virus safety of alpha 1-proteinase inhibitor.
    Coan MH; Dobkin MB; Brockway WJ; Mitra G
    Eur Respir J Suppl; 1990 Mar; 9():35s-38s. PubMed ID: 2340049
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Charge modification of plasma and milk proteins results in antiviral active compounds.
    Swart PJ; Harmsen MC; Kuipers ME; Van Dijk AA; Van Der Strate BW; Van Berkel PH; Nuijens JH; Smit C; Witvrouw M; De Clercq E; de Béthune MP; Pauwels R; Meijer DK
    J Pept Sci; 1999 Dec; 5(12):563-76. PubMed ID: 10628656
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of GB virus C, HIV, and HCV infection markers in hemophiliacs exposed to non-inactivated or inactivated factor concentrates.
    Kupfer B; Ruf T; Matz B; Nattermann J; Spengler U; Rockstroh JK; Brackmann HH; Blümel J; Tacke M; Kaiser R
    J Clin Virol; 2005 Sep; 34(1):42-7. PubMed ID: 16087123
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Enhancement in the safety of immune globulins prepared from high-risk plasma.
    Gao F; Prince AM; Pascual D; Horowitz B
    Vox Sang; 1993; 64(4):204-9. PubMed ID: 8390765
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pathogen inactivation and removal methods for plasma-derived clotting factor concentrates.
    Klamroth R; Gröner A; Simon TL
    Transfusion; 2014 May; 54(5):1406-17. PubMed ID: 24117799
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Industrial pasteurization of plasma and criteria of quality].
    Burnouf-Radosevich M; Burnouf T; Huart JJ
    Rev Fr Transfus Hemobiol; 1993 Jan; 36(1):93-102. PubMed ID: 8476493
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inactivation and partition of human immunodeficiency virus during Kistler and Nitschmann fractionation of human blood plasma.
    Hénin Y; Maréchal V; Barré-Sinoussi F; Chermann JC; Morgenthaler JJ
    Vox Sang; 1988; 54(2):78-83. PubMed ID: 2453974
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Validation of removal of human retroviruses.
    Marcus-Sekura CJ
    Dev Biol Stand; 1992; 76():215-23. PubMed ID: 1478339
    [No Abstract]   [Full Text] [Related]  

  • 52. Preparation and properties of alpha 1-proteinase inhibitor concentrate from human plasma.
    Coan MH; Brockway WJ; Eguizabal H; Krieg T; Fournel M
    Vox Sang; 1985; 48(6):333-42. PubMed ID: 3874474
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ethanol and heat-treated plasma fractionation methods in South Africa.
    Schneider W
    Vox Sang; 1979; 36(6):376. PubMed ID: 494577
    [No Abstract]   [Full Text] [Related]  

  • 54. [Studies on HIV inactivation in allogeneic bone transplants using chemical disinfection and radioactive irradiation].
    Knaepler H; Koch F; Bugany H
    Unfallchirurgie; 1992 Feb; 18(1):1-6. PubMed ID: 1549881
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Modern plasma fractionation.
    Burnouf T
    Transfus Med Rev; 2007 Apr; 21(2):101-17. PubMed ID: 17397761
    [TBL] [Abstract][Full Text] [Related]  

  • 56. “Go no Go” in plasma fractionation in the world’s emerging economies: still a question asked 70 years after the COHN process was developed!
    Burnouf T; Seghatchian J
    Transfus Apher Sci; 2014 Oct; 51(2):113-9. PubMed ID: 25457750
    [TBL] [Abstract][Full Text] [Related]  

  • 57. On the mechanism of the cold ethanol precipitation method of plasma protein fractionation.
    van Oss CJ
    J Protein Chem; 1989 Oct; 8(5):661-8. PubMed ID: 2610860
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ethanol and heat-treated plasma fractionation methods in South Africa.
    de Villiers V; Wilson JG
    Vox Sang; 1978; 35(6):405-11. PubMed ID: 746634
    [TBL] [Abstract][Full Text] [Related]  

  • 59. New trends in plasma fractionation and plasma products.
    Burnouf T
    Vox Sang; 1994; 67 Suppl 3():251-3. PubMed ID: 7975504
    [No Abstract]   [Full Text] [Related]  

  • 60. High-temperature short-time heat inactivation of HIV and other viruses in human blood plasma.
    Charm SE; Landau S; Williams B; Horowitz B; Prince AM; Pascual D
    Vox Sang; 1992; 62(1):12-20. PubMed ID: 1374578
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.